Fig 1.
Number of hospitals with percutaneous coronary intervention capability (PCI H.) versus without (Non-PCI H.) that enrolled acute STEMI patients in the study per each Arabian Gulf country.
Table 1.
Demographics, clinical features, education, and socioeconomic characteristics of patients with acute STEMI transported to the hospital by an emergency medical service (EMS) or alternative transportation (non-EMS).
Fig 2.
Evidence-based treatments administered in the first 24 hours of hospital admission in acute STEMI patients that arrived to the hospital by an emergency medical service (EMS) versus not (non-EMS).
Other aniplatelets, clopidogrel, prasugrel, ticagrelor; BB, beta-blockers; ACE-I/ARB, angiotensin-converting enzyme inhibitors/Angiotensin-receptor blockers, Heparins, unfractionated or low-molecular weight heparin; GP 2b/3a-I, glycoprotein 2bb/3a inhibitors.
Fig 3.
Median time-line of events from symptoms-onset to the administration of reperfusion therapies (total ischemic time) in acute STEMI patients that arrived to the hospital by an emergency medical service (EMS) versus not (non-EMS).
SO, symptoms-onset, FMC, first medical contact; ED, Emergency Department arrival, ECG, electrocardiogram; TT/PPCI, thrombolytic therapy/primary percutaneous coronary intervention.
Table 2.
Univariate and multivariate predictors of emergency medical service (EMS) use among patients with acute STEMI.
Table 3.
In-hospital outcomes, complications, and mortality in patients with acute STEMI transported to the hospital by an emergency medical service (EMS) or alternative transportation (non-EMS).